INDV
Indivior Pharmaceuticals IncNASDAQHealthcare$30.47-0.59%ClosedMarket Cap: $3.80B
As of 2026-04-06
Valuation
View DetailsP/E (TTM)
18.10
PEG
0.03
P/B
-38.80
P/S
3.06
EV/EBITDA
13.13
DCF Value
$2.79
FCF Yield
-2.3%
Div Yield
0.0%
Margins & Returns
Gross Margin
80.3%
Operating Margin
24.4%
Net Margin
16.9%
ROE
-98.9%
ROA
17.4%
ROIC
80.9%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $358.0M | $103.0M | $0.79 |
| FY 2025 | $1.24B | $210.0M | $1.64 |
| Q3 2025 | $314.0M | $42.0M | $0.33 |
| Q2 2025 | $302.0M | $18.0M | $0.14 |
Analyst Ratings
View AllHC Wainwright & Co.Buy
2026-01-12Piper SandlerOverweight
2025-10-31HC Wainwright & Co.Buy
2025-10-30Craig-HallumBuy
2025-08-27Craig-HallumBuy
2025-06-30Trading Activity
Insider Trades
View AllPreblick Ryanofficer: Chief Financial Officer
SellTue Mar 17
Preblick Ryanofficer: Chief Financial Officer
SellTue Mar 17
Ryan Barbaradirector
BuyFri Mar 13
Ryan Barbaradirector
BuyWed Mar 11
Kingsley Stuart Adirector
BuyWed Mar 11
Company Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
1.21
Indivior Pharmaceuticals Inc is a holding company, which engages in the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence. Its products include Suboxone Film, Suboxone Tablet, and Subutex Tablet. It operates through the following geographical segments: United States, Rest of World, and United Kingdom. The company was founded on September 26, 2014 and is headquartered in North Chesterfield, VA.